الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
Hepatitis B virus (HBV) cannot be eliminated completely from
infected hepatocytes because of the presence of intrahepatic
covalently closed circular DNA (cccDNA). As chronic hepatitis B
(CHB) can progress to cirrhosis and hepatocellular carcinoma (HCC),
it is important to manage CHB to prevent HCC development in high
risk patients with high viral replicative activity or advanced fibrosis.
Traditional serum biomarkers are non-invasive and valuable for the
management of CHB but proved insufficient for early detection of
HCC. In this study we aimed to evaluate the HBcrAg as a marker for
hepatocellular carcinoma in patients with chronic hepatitis B.
Subjects:
group I: included 30 patients diagnosed with HCC on top of CHB.
group II: included 30 patients with chronic Hepatitis B, without
HCC.
group III: included 30 normal control subjects with matched age
and sex.
Method:
By enzyme-linked immunosorbent assay (ELISA).
Results: There was a significant difference in age between the
groups, although there was no significant difference in gender distribution between the groups.